CIRCULATING LEVELS OF sCD40L, sFas, VCAM-1 and ICAM-1 IN ACUTE AND CHRONIC ISCHEMIC HEART FAILURE IN MALE PATIENTS | ||||
| Bulletin of Egyptian Society for Physiological Sciences | ||||
| Article 9, Volume 30, Issue 2, June 2010, Page 149-163 PDF (220.2 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/besps.2010.36305 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
| Magdy Al-Tahhan* 1; Etewa L1; Amal Aziz2; Abd El Aziz Gomaa3 | ||||
| 1Medical Biochemistry Department, Faculty of Medicine, Zagazig University. | ||||
| 2Clinical Pathology Department, Faculty of Medicine, Cairo University | ||||
| 3Cardiology Department, Faculty of Medicine, Zagazig University | ||||
| Abstract | ||||
| Background and aim of work: Immunomodulatory mediators play a crucial role in the pathogenesis of heart failure (HF). Vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-l (ICAM-1) are important inflammatory mediators of leukocyte adhesion to vascular endothelium and their plasma levles increase in chronic and acute inflammation. Furthermore, the immune modulators CD40 ligand (CD40L) and sFas have been receiving increased attention, since they play a key role in the pathophysiology of multicellular vascular events such as thrombosis, inflammation, and atherosclerosis. Based on the previous facts, we planned to evaluate the role of plasma VCAM-1, ICAM-1, and serum soluble CD40L (sCD40L) and sFas in HF. Subjects and methods: The present study was done on 30 male patients with HF who were classified according to the type of HF to: 15 patients with chronic HF (CHF) due to ischemic causes and 15 patients with acute myocardial infarction (AMI) complicated with HF during acute phase (AHF). Ten age-matched healthy male volunteers were taken as controls. Plasma levels of VCAM-1, ICAM-1, and serum levels of sCD40L and sFas were measured in all groups. Lipid profile, creatine phosphokinase and its MB fraction were also measured. Results: There were significant increase in plasma levels of VCAM-1 (P<0.05), ICAM-1 (P<0.001), and serum levels of sCD40L (P<0.001) and sFas (P<0.001) in both CHF and AHF patients compared to control subjects. There was a significant positive correlation between VCAM-1 and sCD40L, as well as sFas in CHF (r = 0.46, P = 0.03 and r = 0.47, P = 0.02 respectively) and a significant positive correlation between ICAM-1 and sCD40L, as well as sFas in AHF (r = 0.551, P<0.01 and r = 0.49, P = 0.012 respectively). Also, there was a positive significant correlation between sCD40L and low-density lipoprotein cholesterol in both CHF and AHF cases (P<0.05). Conclusion: sCD40L, sFas, VCAM-1, and ICAM-1 could be used as markers that might predict cardiovascular events in patients with chronic and acute heart diseases. | ||||
| Keywords | ||||
| sCD40L; sFas; VCAM-1 and ICAM-1; Heart failure | ||||
|
Statistics Article View: 79 PDF Download: 74 |
||||
